

INTESTINAL MICROBIOME ANALYSIS REQUEST

cod. S 20 date 11/04/2024 rev. 0

| Last and First Name: | |
|------------------------|-------------------|
| Responsible Physician: | Date of delivery: |

SAMPLE TYPE

☐ GASTROINTESTINAL

PREPARATION FOR TEST, SAMPLE STORAGE AND DELIVERY

Feces should be from a single visceral movement and collected in sterile container.

The retrieved material should be stored at 2-8°C for 24h or at -20°C for up to one week. The amount needed to perform the test is about 600 mg (take an amount equal to the size of a walnut).

| Compiled by | Verified by | Approved by |
|---------------------------------------|--|---|
| Laboratory Director Dr. Laura Soldini | Quality Assurance Safety Environment Dr. Stefania Fazzone | Health Management Dr. Gabriele Pellicciotta |

064/7 page 1 of 2



INTESTINAL MICROBIOME ANALYSIS REQUEST

cod. S 20 date 11/04/2024 rev. 0

We kindly request that you complete the following questionnaire regarding the patient's clinical information and medications taken.

| Use of one or more of the following | | <u>'</u> | | | | |
|--|--------------------|--|---------------------|---|---------------|--|
| □ Systemic antibiotics (oral, intravend | | - | | | | |
| ☐ Antifungals, antivirals, and antipara | asitics for syster | nic use (orai, intravenous | s, intramuscular) | | | |
| □ Corticosteroids | | | | | | |
| □ Cytokines | | | | | | |
| ☐ Immunosuppressants (e.g., methot | | | | | | |
| □ Probiotics (daily intake at high dose | | | capsules, lozenge | es, chewing gun | ۱, or | |
| powders in which the probiotic is a p | rimary compon | ent) | | | | |
| Acute disease at the time of sampling | ıø | | | | | |
| □ gastrointestinal | . | | | | | |
| □ cardiovascular | | | | | | |
| □ pulmonary | | | | | | |
| □ hepatic | | | | | | |
| □ renal | | | | | | |
| | | | | | | |
| Chronic disease at the time of sample | ling | | | | | |
| □ gastrointestinal | | | | | | |
| □ cardiovascular | | | | | | |
| □ pulmonary | | | | | | |
| □ hepatic | | | | | | |
| □ renal | | | | | | |
| Gastrointestinal disorders | | | | | | |
| □ Inflammatory bowel disease (mild- | moderate-seve | re) (e.g. ulcerative colitis | Crohn's dispass | and determine | ad colitis) | |
| □ irritable bowel syndrome (IBS) (mo | | re) (e.g., dicerative contis | s, cromms disease | s and determine | zu contis) | |
| □ infectious gastroenteritis (colitis or | | | | | | |
| □ clostridim difficile infection (recurr | - | | | | | |
| □ helicobacter pylori infection (untre | • | | | | | |
| persistent or chronic diarrhea of ur | | ı | | | | |
| □ chronic constipation | ikilowii ctiologi | 1 | | | | |
| | | | | | | |
| Pre-existing colorectal cancer | □ Yes | □ No | | | | |
| Unstable dietary history characterize | | anges in diet during the I | month prior to s | ampling, such a | <u>IS</u> | |
| elimination or increase of a specific | | □ Yes □ No | | | | |
| Chronic alcohol consumption (define | ed as daily cons | umption of 0.2 L of disti | lled spirits, 1.7 L | of beer, or 0.7 | L of wine) | |
| | | | | □ Yes | □ No | |
| Gastrointestinal tract surgeries in th | e past five vear | r s □ Yes | □ No | □ 1 C 3 | - 1 10 | |
| | | | | | | |
| Pregnant or lactating | □ Yes | □ No | | | | |
| Positive test for HIV, HBV or HCV | □ Yes | □ No | | | | |
| | | | | | | |
| Compiled by | | Verified by | | Approved by | | |
| Laboratory Director Dr. Laura Soldini | Quality Assu | Quality Assurance Safety Environment Dr. | | Health Management Dr. Gabriele Pellicciotta | | |
| | ı | Stefania Fazzone | I | | | |

064/7 page 2 of 2